Traditional Chinese Medicine for Treatment of Chronic Heart Failure

NCT01939236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2013-10-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether traditional Chinese medicine as complementary treatment is safe and effective in the treatment of chronic heart failure.

Conditions

Interventions

DRUG

traditional Chinese medicine

1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.

DRUG

Placebo (gummeline)

Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation. 1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days.

Sponsors & Collaborators

  • Wuhan Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Zhengzhou Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Changchun University of Chinese Medicine

    collaborator OTHER
  • Hubei Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Yichang Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Dongzhimen Hospital, Beijing

    collaborator OTHER
  • Guang'an Men Hospital Affiliated to China Academy of Chinese Medicine Sciences

    collaborator UNKNOWN
  • Beijing University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Wei Wang, Doctor · Beijing University of Chinese Medicine

  • Peng Zhang, Doctor · Wuhan Hospital of Chinese Medicine

  • Huihui Zhao, Doctor · Beijing University of Chinese Medicine

  • Liangtao Luo, Master · Beijing University of Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939236 on ClinicalTrials.gov